Efficacy of a recombinant fowl pox-based Newcastle disease virus vaccine candidate against velogenic and respiratory challenge.
A fowl pox-based recombinant virus TROVAC-NDV (vFP96.5) was developed expressing the fusion and hemagglutinin-neuraminidase glycoproteins from a velogenic strain of Newcastle disease virus (NDV). Studies in specific-pathogen-free birds indicated that inoculation of a single dose of the recombinant led to the induction of significant levels of hemagglutination-inhibiting antibody that were maintained to 8 wk postinoculation. Further, the recombinant induced protective immunity against a combined intramuscular velogenic NDV challenge and respiratory NDV challenge. In commercial broiler chickens that were inoculated in the presence of maternally derived NDV immunity, the level of the NDV-specific humoral response was dampened, but significant levels of protection against both a lethal intramuscular NDV challenge and a fowl poxvirus challenge were obtained.
Taylor
J
J
Virogenetics Corporation, Troy, New York 12180, USA.
Christensen
L
L
Gettig
R
R
Goebel
J
J
Bouquet
J F
JF
Mickle
T R
TR
Paoletti
E
E
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D002645:Chickens; D005260:Female; D005586:Fowlpox / Q000097:blood / Q000276:immunology / Q000517:prevention & control*; D005587:Fowlpox virus / Q000276:immunology*; D007273:Injections, Intramuscular / Q000662:veterinary; D007279:Injections, Subcutaneous / Q000662:veterinary; D009521:Newcastle Disease / Q000097:blood / Q000276:immunology / Q000517:prevention & control*; D009522:Newcastle disease virus / Q000276:immunology*; D009883:Ophthalmic Solutions / Q000008:administration & dosage; D011994:Recombinant Proteins / Q000276:immunology; D013047:Specific Pathogen-Free Organisms; D016896:Treatment Outcome; D014612:Vaccines; D014765:Viral Vaccines / Q000008:administration & dosage*
D000914:Antibodies, Viral; D009883:Ophthalmic Solutions; D011994:Recombinant Proteins; D014612:Vaccines; D014765:Viral Vaccines